Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Perfluorohexyloctane · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Arm 3 | ACTIVE_COMPARATOR | - |
| Arm 4 | PLACEBO_COMPARATOR | - |
| Arm 5 | PLACEBO_COMPARATOR | - |
| Arm 6 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Lifitegrast/Perfluorohexyloctane Fixed Dose Combination | DRUG | Topical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks |
| Lifitegrast | DRUG | Topical ocular drop of lifitegrast administered for 4 weeks |
| Perfluorohexyloctane | DRUG | Topical ocular drop of perfluorohexyloctane administered for 4 weeks |
| Vehicle | DRUG | Topical ocular drop with no active ingredients administered for 4 weeks |
Inclusion Criteria: This study will include subjects who meet all of the following inclusion criteria: * Voluntarily provide written informed consent * ≥18 years of age * Subject-reported history of DED OU for at least 6 months * Same eye satisfies the criteria for dry eye signs at both screening ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | ABBV-444, REFRESH OPTIVE UD |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Alcon AG | ALC | 1 | N/A | Undisclosed |
| Harrow, Inc. | HROW | 1 | - | Undisclosed |
Perfluorohexyloctane is an investigational small molecule being developed for Dry Eye Disease. It is a semifluorinated alkane that is being studied for its potential to treat the signs and symptoms of dry eye. The drug is currently in clinical development and has not been approved by the FDA.
Perfluorohexyloctane is being developed by Bausch + Lomb Corporation, a company traded on the New York Stock Exchange under the ticker symbol BLCO. Bausch + Lomb is a global eye health company that focuses on developing and commercializing products for ophthalmology.
Perfluorohexyloctane is in Phase 2 clinical development for Dry Eye Disease. It has completed one Phase 2 trial, and the drug remains investigational. It has not been approved by the FDA, and its safety and efficacy have not been fully established.
Perfluorohexyloctane has been studied in one completed Phase 2 clinical trial with the identifier NCT07128628. This trial was a randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of a fixed-dose combination for Dry Eye Disease. The trial enrolled 443 participants in the United States.
Perfluorohexyloctane is also known by its chemical name and is sometimes referred to as a semifluorinated alkane. It is being studied as a fixed-dose combination for Dry Eye Disease, but no alternative brand names have been established for this investigational drug.